-9.0%
HUM vs GSK
+47.2%
-56.2%
-67.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.3% | 0.0% | +2.2% | +2.3% |
| 7D | +2.1% | -3.5% | +5.6% | +2.5% |
| 30D | +5.4% | -3.4% | +8.8% | +5.7% |
| 3M | +11.4% | -8.1% | +19.5% | +12.4% |
| 6M | +141.5% | -11.1% | +152.6% | +144.0% |
| YTD | +61.2% | +0.7% | +60.4% | +59.4% |
| 1Y | +49.2% | +20.1% | +29.0% | +42.8% |
| 3Y | -9.0% | +46.1% | -55.2% | -18.5% |
| All | -9.0% | +47.2% | -56.2% | -18.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling